Related Experiment Videos
[Branched chain amino acid diseases]
Acta Medica Portuguesa
|December 22, 1998
Summary
Branched-chain amino acid (BCAA) catabolism diseases, including Maple Syrup Urine Disease, require prompt diagnosis and treatment, often involving extracorporeal procedures. Early intervention improves outcomes, though mortality and neurological deficits remain significant concerns.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Context:
- Branched-chain amino acid (BCAA) catabolism disorders are rare genetic conditions.
- These diseases disrupt essential metabolic pathways, leading to toxic metabolite accumulation.
- Early diagnosis and management are critical for patient outcomes.
Purpose:
- To analyze clinical data from 19 patients with various BCAA catabolism diseases.
- To evaluate the efficacy of extracorporeal procedures and identify risk factors for mortality and neurological deficits.
- To emphasize the importance of timely diagnosis and treatment across all age groups.
Summary:
- The study reviewed 19 cases of BCAA catabolism diseases, including Maple Syrup Urine Disease (MSUD), Methylmalonic Acidemias (MMA), and Propionic Acidemias (PA).
- Fifteen patients (78.9%) required extracorporeal procedures, and 26.3% experienced fatal outcomes, particularly among neonatal forms.
- While 57.9% of survivors had normal cognitive function (IQ/DQ ≥ 80), late-onset forms showed better cognitive outcomes than neonatal ones.
Impact:
- Highlights the significant mortality and morbidity associated with BCAA catabolism disorders.
- Underscores the need for heightened clinical suspicion and early diagnostic approaches, especially in neonates.
- Informs treatment strategies, emphasizing extracorporeal procedures and the long-term management of neurological sequelae.